Han G R, Cai G F
Dalian Rail-Way Hospital.
Zhonghua Fu Chan Ke Za Zhi. 1993 Apr;28(4):224-6, 254.
Ten patients with surgically and pathologically confirmed ovarian cancer were treated by intraperitoneal (IP) chemotherapy of 20-25 mg/m2 of cisplatin. Total platinum concentrations in plasma, ascitic fluid and urine were determined by flameless atomic absorption spectrophotometry. The peak of total platinum concentration in ascitic fluid was 18.75 times greater than that in plasma. The half-life of the elimination for total ascites platinum and total plasma platinum were 39.9 hours and 70.6 hours respectively. Peritoneal clearance of cisplatin was 6.1 ml/min whereas body clearance of cisplatin was 15.3 ml/min. 24 hours following administration, 13.53% of cisplatinum had been excreted through the urine. The results indicate that there is pharmacokinetic advantage to be gained by using IP chemotherapy of cisplatin. Because the half-life of cisplatin in plasma is longer, therefore, the interval of chemotherapy should be three weeks or more.
10例经手术和病理确诊的卵巢癌患者接受了顺铂20 - 25mg/m²的腹腔内(IP)化疗。采用无火焰原子吸收分光光度法测定血浆、腹水和尿液中的总铂浓度。腹水中总铂浓度峰值比血浆中高18.75倍。腹水总铂和血浆总铂的消除半衰期分别为39.9小时和70.6小时。顺铂的腹膜清除率为6.1ml/min,而顺铂的机体清除率为15.3ml/min。给药后24小时,13.53%的顺铂经尿液排出。结果表明,采用顺铂腹腔内化疗具有药代动力学优势。由于顺铂在血浆中的半衰期较长,因此,化疗间隔应为三周或更长时间。